Veru reports second quarter fiscal 2022 results and progress of sabizabulin for covid-19 toward a request for emergency use authorization

--fda states that veru should submit request for emergency use authorization (eua) application based on positive efficacy and safety data from the phase 3 clinical study of sabizabulin in hospitalized covid-19 patients-- --idmc unanimously votes to halt the ongoing phase 3 trial of sabizabulin for hospitalized covid-19 patients at high risk of ards due to overwhelming efficacy and safety with 55.2% reduction in death--
VERU Ratings Summary
VERU Quant Ranking